- Home
- QURE vs EOLS Comparison
QURE vs EOLS Comparison
Compare QURE & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QURE
- EOLS
- Stock Information
- Founded
- QURE 1998
- EOLS 2012
- Country
- QURE Netherlands
- EOLS United States
- Employees
- QURE N/A
- EOLS N/A
- Industry
- QURE Biotechnology: Pharmaceutical Preparations
- EOLS Biotechnology: Pharmaceutical Preparations
- Sector
- QURE Health Care
- EOLS Health Care
- Exchange
- QURE Nasdaq
- EOLS Nasdaq
- Market Cap
- QURE 860.8M
- EOLS 702.2M
- IPO Year
- QURE 2007
- EOLS 2018
- Fundamental
- Price
- QURE $15.18
- EOLS $14.10
- Analyst Decision
- QURE Strong Buy
- EOLS Strong Buy
- Analyst Count
- QURE 8
- EOLS 6
- Target Price
- QURE $33.00
- EOLS $22.60
- AVG Volume (30 Days)
- QURE 1.2M
- EOLS 695.8K
- Earning Date
- QURE 02-26-2025
- EOLS 03-06-2025
- Dividend Yield
- QURE N/A
- EOLS N/A
- EPS Growth
- QURE N/A
- EOLS N/A
- EPS
- QURE N/A
- EOLS N/A
- Revenue
- QURE $28,587,000.00
- EOLS $248,326,000.00
- Revenue This Year
- QURE $153.92
- EOLS $33.43
- Revenue Next Year
- QURE N/A
- EOLS $32.44
- P/E Ratio
- QURE N/A
- EOLS N/A
- Revenue Growth
- QURE N/A
- EOLS 34.42
- 52 Week Low
- QURE $3.73
- EOLS $9.25
- 52 Week High
- QURE $19.18
- EOLS $17.82
- Technical
- Relative Strength Index (RSI)
- QURE 52.73
- EOLS 68.82
- Support Level
- QURE $13.70
- EOLS $9.25
- Resistance Level
- QURE $15.18
- EOLS $14.49
- Average True Range (ATR)
- QURE 1.07
- EOLS 0.64
- MACD
- QURE -0.54
- EOLS 0.42
- Stochastic Oscillator
- QURE 29.76
- EOLS 87.02
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About EOLS Evolus Inc.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.